These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 7964124)

  • 21. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
    Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
    Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes.
    Ponka P; Schulman HM; Wilczynska A
    Biochim Biophys Acta; 1982 Oct; 718(2):151-6. PubMed ID: 7138909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.
    Hershko C; Avramovici-Grisaru S; Link G; Gelfand L; Sarel S
    J Lab Clin Med; 1981 Jul; 98(1):99-108. PubMed ID: 7252329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilize iron from reticulocytes in vitro: reappraisal of reported partition coefficients.
    Edward JT; Chubb FL; Sangster J
    Can J Physiol Pharmacol; 1997 Dec; 75(12):1362-8. PubMed ID: 9534947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes.
    Ponka P; Richardson D; Baker E; Schulman HM; Edward JT
    Biochim Biophys Acta; 1988 Oct; 967(1):122-9. PubMed ID: 3167093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells.
    Buss JL; Arduini E; Shephard KC; Ponka P
    Biochem Pharmacol; 2003 Feb; 65(3):349-60. PubMed ID: 12527328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Examination of the mechanism of action of nitrogen monoxide on iron uptake from transferrin.
    Watts RN; Richardson DR
    J Lab Clin Med; 2000 Aug; 136(2):149-56. PubMed ID: 10945243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties.
    Buss JL; Neuzil J; Gellert N; Weber C; Ponka P
    Biochem Pharmacol; 2003 Jan; 65(2):161-72. PubMed ID: 12504792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The release of iron and transferrin from the human melanoma cell.
    Richardson DR; Baker E
    Biochim Biophys Acta; 1991 Feb; 1091(3):294-302. PubMed ID: 2001412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain iron homeostasis.
    Moos T
    Dan Med Bull; 2002 Nov; 49(4):279-301. PubMed ID: 12553165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone.
    Cikrt M; Ponka P; Necas E; Neuwirt J
    Br J Haematol; 1980 Jun; 45(2):275-83. PubMed ID: 7437326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs.
    Johnson DK; Pippard MJ; Murphy TB; Rose NJ
    J Pharmacol Exp Ther; 1982 May; 221(2):399-403. PubMed ID: 7077535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation.
    Le NT; Richardson DR
    Carcinogenesis; 2003 Jun; 24(6):1045-58. PubMed ID: 12807743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pyridoxal isonicotinoyl hydrazone (PIH): a promising new iron chelator.
    Webb J; Vitolo ML
    Birth Defects Orig Artic Ser; 1988; 23(5B):63-70. PubMed ID: 3291971
    [No Abstract]   [Full Text] [Related]  

  • 35. Transferrin-bound and transferrin free iron uptake by cultured rat astrocytes.
    Qian ZM; Liao QK; To Y; Ke Y; Tsoi YK; Wang GF; Ho KP
    Cell Mol Biol (Noisy-le-grand); 2000 May; 46(3):541-8. PubMed ID: 10872741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemical studies of pyridoxal isonicotinoyl hydrazone relevant to its clinical evaluation.
    Vitolo ML; Clare BW; Hefter GT; Webb J
    Birth Defects Orig Artic Ser; 1988; 23(5B):71-9. PubMed ID: 3390576
    [No Abstract]   [Full Text] [Related]  

  • 37. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression.
    Gao J; Richardson DR
    Blood; 2001 Aug; 98(3):842-50. PubMed ID: 11468187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells.
    Fan L; Iyer J; Zhu S; Frick KK; Wada RK; Eskenazi AE; Berg PE; Ikegaki N; Kennett RH; Frantz CN
    Cancer Res; 2001 Feb; 61(3):1073-9. PubMed ID: 11221835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tritrichomonas foetus: iron acquisition from lactoferrin and transferrin.
    Tachezy J; Kulda J; Bahníková I; Suchan P; Rázga J; Schrével J
    Exp Parasitol; 1996 Jul; 83(2):216-28. PubMed ID: 8682190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PCTH: a novel orally active chelator for the treatment of iron overload disease.
    Lovejoy DB; Kalinowski D; Bernhardt PV; Richardson DR
    Hemoglobin; 2006; 30(1):93-104. PubMed ID: 16540421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.